For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
We have purchased anti-EGF antibody (ab9695)in your company. I would like to kindly ask if you could provide more information regarding epitope of this antibody? We would like to know if the anti-EGF ab is suitable for co-immunoprecipitaion with EGFR? Does the antibody binding site co-localize with EGFR binding site, thus blocking interaction between EGF and its receptor EGFR?
Thank you for your help
Asked on Feb 11 2013
Thank you very much for your inquiry.
The immunogen for ab9695 was the full length recombinant hEGF (human Epidermal Growth Factor) and it therefore impossible to determine an epitope.
It is possible to determine experimentally if the antibody blocks the binding site of EGFR, but this has not been done and also would have to be repeated with every new immunization round (for every batch of antibody).
To our knowledge, ab9695 has not been tested in immunoprecipitation and therefore is also not covered by our guarantee for this application. However by participating in our AbTrial program you can now use our products in an untested application or species without financial risk.
Simply follow these easy steps below to apply for our AbTrial Program:
1. Reply to this email, letting us know you are interested in testing this product.
2. Our scientists will email you an inactive personal discount code for the value of the product.
3. Purchase and test the product at the regular price.
4. Submit your results, including your discount code in the additional notes section of your Abreview.
5. Once the Abreview is submitted, the discount code will become active.
6. Apply your discount code on your next order to receive that value off.
Please let me know if you have any questions about this offer and I would be happy to help you further.
The Terms and Conditions of this offer can be found at: www.abcam.com/abtrial.
Answered on Feb 11 2013